miR-219a-5p通过调控NEK6基因表达抑制视网膜母细胞瘤增殖、迁移和侵袭的机制

目的探讨miR-219a-5p对视网膜母细胞瘤(RB)增殖、迁移和侵袭的影响及作用机制。方法 qRT-PCR检测人RB细胞Y79与正常人视网膜血管内皮细胞ACBRI-181中miR-219a-5p和NEK6 mRNA的表达,Western印迹检测NEK6蛋白表达。分别转染miR-219a-5p mimics和si-NEK6至Y79细胞,四甲基偶氮唑蓝(MTT)检测细胞增殖,Transwell检测细胞迁移和侵袭,Western印迹检测周期蛋白依赖性激酶(CDK)1、细胞周期蛋白(Cyclin)D1、基质金属蛋白酶(MMP)-2和MMP-9蛋白表达。双荧光素酶报告基因实验验证miR-219a-5p和NEK6的靶向关系。结果 Y79细胞中miR-219a-5p低表达,NEK6 mRNA和蛋白高表达。miR-219a-5p过表达或抑制NEK6表达可抑制Y79细胞增殖、迁移和侵袭,下调Y79细胞CDK1、Cyclin D1、MMP-2和MMP-9蛋白表达。miR-219a-5p在Y79细胞中靶向负调控NEK6表达,NEK6过表达可逆转miR-219a-5p过表达对Y79细胞增殖、迁移和侵袭的抑制作用。结论 miR-219a-5p调控NEK6表达抑制Y79细胞的增殖、迁移和侵袭能力,是治疗RB的新靶点。     

普鲁卡因通过miR-15a-5p/PI3K-AKT3途径调控乳腺癌细胞增殖、迁移和侵袭的机制

目的探讨普鲁卡因对乳腺癌细胞MCF-7增殖、迁移和侵袭的影响及其作用机制。方法以不同浓度(0.5、1.0、2.5、5.0、10.0 mmol/L)普鲁卡因处理MCF-7细胞,噻唑蓝(MTT)法检测细胞增殖;5.0 mmol/L普鲁卡因处理MCF-7细胞48 h后,Transwell法检测迁移和侵袭,实时荧光定量-聚合酶链反应(qRT-PCR)检测miR-15a-5p的表达。转染miR-15a-5p mimic至MCF-7细胞,检测细胞增殖、迁移和侵袭。靶基因预测软件预测miR-15a-5p和AKT3靶向结合位点,双荧光素酶报告基因实验检测二者靶向关系。转染miR-15a-5p inhibitor至MCF-7细胞,并用5.0 mmol/L普鲁卡因处理48 h,检测细胞增殖、迁移和侵袭,Western印迹检测蛋白激酶B(AKT)3的表达。结果与Con组相比,普鲁卡因能明显抑制MCF-7细胞增殖、迁移和侵袭(P<0.001),促进细胞中miR-15a-5p的表达(P<0.01)。过表达miR-15a-5p可抑制MCF-7细胞增殖、迁移和侵袭(P<0.001,P<0.01,P<0.05)。双荧光素酶报告基因实验证实miR-15a-5p和AKT3的靶向结合有关。抑制miR-15a-5p表达减弱了普鲁卡因对MCF-7细胞增殖、迁移、侵袭及AKT3表达的抑制作用(P<0.05)。结论普鲁卡因能够抑制乳腺癌细胞MCF-7的增殖、迁移和侵袭能力,其机制可能与调控miR-15a-5p/磷脂酰肌激-3-激酶(PI3K)-AKT3途径有关。     

miR-216a-5p调控XIAP对急性胰腺炎腺泡细胞增殖、凋亡的影响

背景重症急性胰腺炎(acute pancreatitis, AP)是消化系统常见的危重急症,临床救治难度大,病死率高,严重危及患者生命.近几年来多种miRNA在AP中的差异表达,与其发生发展及诊断和预后密切相关,进一步探索其在AP发生发展、并发症等各环节的作用有助于为AP的诊断和治疗提供新的思路和方法.研究发现miR-216a-5p通过下调MMP16可抑制肺癌细胞的侵袭; miR-216a-5p通过靶向抑制PAK2基因可抑制膀胱癌细胞的增殖能力,促进细胞凋亡. miR-216a-5p可抑制小细胞肺癌的恶性进展,影响前列腺癌细胞的增殖、迁移和宫颈癌细胞的肿瘤发生.仅发现miR-216a在AP患者外周血中高表达,但miR-216a-5p在AP的增殖凋亡中的影响及作用机制尚不清楚.目的研究miR-216a-5p对AP腺泡细胞增殖、凋亡的影响及潜在的作用机制.方法用雨蛙素(caerulein, CAE)处理大鼠胰腺腺泡AR42J构建AP模型,设置miR-NC组(转染miR-NC)、miR-216a-5p组(miR-216a-5pmimics)、anti-miR-NC组(转染antimiR-NC)、anti-miR-216a-5p组(转染anti-miR-216a-5p)、pcDNA3.1组(转染pc DNA3.1)、pcDNA3.1-XIAP组(转染pcDNA3.1-XIAP)、anti-miR-216a-5p+si-NC组(共转染anti-miR-216a-5p和si-NC)、anti-miR-216a-5p+si-XIAP(共转染anti-miR-216a-5p和si-XIAP)组,均用脂质体法转染. qRT-PCR检测AR42J细胞中miR-216a-5p的表达水平; Western Blot检测蛋白表达; MTT法检测细胞活性;流式细胞术检测细胞凋亡;双荧光素酶报告基因检测实验检测荧光活性.结果CAE处理AR42J细胞后,miR-216a-5p的表达水平显著升高(P0.05).抑制表达miR-216a-5p和过表达XIAP细胞活性显著升高,细胞凋亡率显著降低, Cyclin D1、Bcl-2蛋白的表达水平显著升高,P21、Bax蛋白的表达水平显著下降(P0.05). miR-216a-5p靶向负调控XIAP;抑制XIAP表达逆转了抑制miR-216a-5p对CAE处理的AR42J细胞增殖促进、凋亡抑制的作用.结论抑制miR-216a-5p表达可以抑制胰腺炎腺泡细胞凋亡,促进细胞增殖,其机制可能与靶向调控XIAP有关.可为AP诊断和治疗提供新靶点和新思路.     

沉默miR-135a-5p对宫颈癌细胞增殖、侵袭的影响及作用机制

目的 探究沉默微小RNA-135a-5p(miR-135a-5p)对人宫颈癌HeLa细胞增殖、凋亡、迁移、侵袭的影响，重点分析miR-135a-5p在宫颈癌HeLa细胞中的作用机制。方法 将宫颈癌HeLa细胞经培育后分为对照组、过表达组、沉默组，对照组不做处理，过表达组转染miR-135a-5p mimics上调载体，沉默组转染miR-135a-5p inhibitor下调载体。使用实时荧光定量法检测每组宫颈癌HeLa细胞中miR-135a-5p表达量；四甲基偶氮唑盐法检测每组宫颈癌HeLa细胞增殖水平；Transwell小室法检测每组宫颈癌HeLa细胞侵袭水平。结果 与对照组比较，过表达组(24 h、48 h、72 h)宫颈癌HeLa细胞增殖能力、miR-135a-5p、宫颈癌HeLa细胞迁移数、侵袭数明显升高，宫颈癌HeLa细胞凋亡能力明显降低(P<0.05);与对照组比较，沉默组(24 h、48 h、72 h)宫颈癌HeLa细胞增殖能力、迁移数、侵袭数、miR-135a-5p明显降低，凋亡能力明显升高(P<0.05);与过表达组比较，沉默组(24 h、48 h、72 ...     

LncRNA ZBTB20-AS1靶向miR-132-3p/MAPT轴影响阿尔茨海默病的发生发展

目的探讨长链非编码(Lnc)RNA锌指蛋白ZBTB20反义RNA1(ZBTB20-AS1)靶向miR-132-3p/微管相关蛋白tau(MAPT)轴对阿尔茨海默病(AD)发生发展的影响。方法采用Aβ_(25～35)(20μmol/L)处理SK-N-SH细胞构建AD细胞模型。将si-con、si-ZBTB20-AS1、miR-con、miR-132-3p mimics、si-MAPT分别转染SK-N-SH细胞,经Aβ_(25～35)处理后,反转录及荧光定量PCR(RT-qPCR)检测ZBTB20-AS1和miR-132-3p的表达水平,噻唑蓝(MTT)法检测细胞增殖活力,流式细胞术检测细胞凋亡,Western印迹检测MAPT、细胞周期蛋白(Cyclin)D1和活化的半胱氨酸天冬氨酸蛋白酶(Cleaved-caspase)-3的表达水平。双荧光素酶报告基因实验验证ZBTB20-AS1和miR-132-3p、miR-132-3p和MAPT的靶向关系。结果 AD细胞模型中ZBTB20-AS1和miR-132-3p的表达水平显著升高,MAPT的表达水平显著降低。沉默ZBTB20-AS1、过表达miR-132-3p或沉默MAPT均可促进SK-N-SH细胞增殖,抑制Aβ_(25～35)诱导的细胞凋亡。miR-132-3p是ZBTB20-AS1的靶基因,ZBTB20-AS1可靶向负性调控miR-132-3p表达。MAPT是miR-132-3p的靶基因,miR-132-3p可靶向调控MAPT表达。抑制miR-132-3p表达或过表达MAPT均可逆转沉默ZBTB20-AS1对Aβ_(25～35)诱导的SK-N-SH细胞增殖和凋亡的影响。结论沉默ZBTB20-AS1通过调控miR-132-3p/MAPT轴可促进SK-N-SH细胞增殖,抑制Aβ_(25～35)诱导的SK-N-SH细胞凋亡。     

miR-129-3p靶向LPAR3调控肝癌细胞增殖、迁移和侵袭的分子机制

目的探讨miR-129-3p靶向LPAR3调控肝癌细胞增殖、迁移和侵袭的分子机制。方法 qRT-PCR和Western blotting检测正常肝细胞HL-7702和3种肝癌细胞SMMC-7721、Hep G2和BEL-7402中miR-129-3p和LPAR3的表达情况。构建过表达miR-129-3p的SMMC-7721细胞株,MTT法检测细胞增殖活力,Transwell法检测细胞迁移和侵袭能力,Western blotting检测LPAR3、Cyclin D1、MMP-2、PI3K和AKT蛋白的表达。采用双荧光素酶报告基因法和Western blotting验证miR-129-3p和LPAR3的靶向关系。结果与正常肝细胞相比,肝癌细胞中miR-129-3p的表达显著降低,LPAR3的表达显著升高。过表达miR-129-3p可抑制SMMC-7721的增殖、迁移和侵袭。LPAR3是miR-129-3p的靶基因,miR-129-3p可负性调控LPAR3的表达。过表达LPAR3可部分逆转miR-129-3p对SMMC-7721细胞的增殖、迁移和侵袭的抑制作用。miR-129-3p通过调控LPAR3抑制PI3K和AKT蛋白的表达。结论 miR-129-3p通过靶向下调LPAR3抑制PI3K/AKT信号通路活化,进而抑制肝癌细胞的增殖、迁移和侵袭。     

miR-520f-3p靶向LAMA3对结直肠癌细胞增殖、迁移的影响

目的 探讨miR-520f-3p靶向层黏连蛋白(LAMA)3对结直肠癌(CRC)细胞增殖、迁移的影响。方法 采用实时荧光定量聚合酶链反应(qRT-PCR)分别检测病理组织样本、正常结直肠细胞FHC及CRC细胞SW480、LOVO、HCT116、HT29中miR-520f-3p表达;Western印迹检测病理组织样本中LAMA3蛋白表达。将对数生长期的LOVO细胞分为对照组、inhibitor NC组、miR-520f-3p inhibitor组、mimics NC组、miR-520f-3p mimics组、miR-520f-3p mimics+pcDNA组、miR-520f-3p mimics+pcDNA-LAMA3组;qRT-PCR检测各组细胞中miR-520f-3p表达;CCK-8法检测各组细胞增殖;划痕实验检测各组细胞迁移;Western印迹检测各组细胞中LAMA3、增殖细胞核抗原(PCNA)、细胞周期蛋白(Cyclin)D1、基质金属蛋白酶(MMP)-2蛋白表达;荧光素酶报告基因实验检测miR-520f-3p与LAMA3的靶向关系;采用裸鼠皮下注射上述LOVO细胞以构建裸鼠体内...     

miR-151a-3p对胰腺癌细胞增殖、迁移、侵袭及凋亡的影响

目的探讨miR-151a-3p在胰腺癌细胞中的表达及miR-151a-3p表达对胰腺癌细胞增殖、迁移、侵袭及凋亡的影响。方法采用实时荧光定量聚合酶链反应(qRT-PCR)检测miR-151a-3p在三种胰腺癌细胞系的表达情况;利用脂质体转染技术将miR-151a-3p mimic和mimic NC转染至胰腺癌BxPC-3细胞中,qRT-PCR检测转染后miR-151a-3p在BxPC-3细胞中的表达水平;CCK-8法检测转染后BxPC-3细胞的增殖能力;Transwell实验检测转染后BxPC-3细胞的迁移及侵袭能力;流式细胞术检测转染BxPC-3细胞的凋亡能力。结果 qRT-PCR结果显示,3种胰腺癌细胞系中miR-151a-3p表达水平均显著升高(P0.01),其中,BxPC-3细胞中miR-151a-3p表达水平最高;转染miR-151a-3p mimic的BxPC-3细胞中miR-151a-3p表达水平显著高于mimic NC和空白组(P0.001);CCK-8实验结果显示,转染miR-151a-3p mimic的BxPC-3细胞增殖能力显著高于mimic NC和空白对照组(P0.01);Transwell实验结果显示,转染miR-151a-3p mimic的BxPC-3细胞迁移及侵袭能力显著高于mimic NC和空白对照组(P0.01);流式细胞术结果显示,转染miR-151a-3p mimic的BxPC-3细胞凋亡率显著低于mimic NC和空白对照组(P0.001)。结论 miR-151a-3p在胰腺癌细胞中高表达,过表达miR-151a-3p促进胰腺癌细胞增殖、迁移及侵袭,抑制细胞凋亡。     

miR-18a-5p调控PSORS1C1对类风湿关节炎成纤维细胞样滑膜细胞迁移、侵袭及炎症反应的影响

目的探讨微小RNA-18a-5p(miR-18a-5p)对类风湿关节炎成纤维细胞(SFs)样滑膜细胞迁移、侵袭及炎症反应的影响及其作用机制。方法体外培养人类风湿关节炎滑膜成纤维细胞MH7A,分为miR-18a-5p组、miR-NC组、si-PSORS1C1组、si-NC组、miR-18a-5p+pcDNA3.1-PSORS1C1组、miR-18a-5p+pcDNA3.1组。qRT-聚合酶链反应(PCR)检测miR-18a-5p表达;分别采用Transwell小室法检测细胞迁移及侵袭的情况。双荧光素酶报告基因实验检测miR-18a-5p与PSORS1C1的靶向关系;Western印迹检测PSORS1C1、基质金属蛋白酶(MMP)-2、钙黏附蛋白-E(E-cadherin)蛋白表达;测定细胞上清液中白细胞介素(IL)-1、IL-2水平。结果 miR-18a-5p在MH7A细胞中的表达水平显著降低(P<0.05),miR-18a-5p过表达可明显抑制MH7A细胞迁移及侵袭能力,IL-1水平与MMP-2表达水平显著降低(P<0.05),而IL-2水平与E-cadherin表达水平均...     

Electrochemical Recovery and Behaviors of Rare Earth (La,Ce, Pr,Nd, Sm,Eu, Gd,Tb, Dy,Ho, Er,Tm, and Yb) Ions on Ni Sheets

The electrochemical behaviors of rare earth (RE) ions have extensively been studied because of their high potential applications to the reprocessing of used nuclear fuels and RE-containing materials. In the present study, we fully investigated the electrochemical behaviors of RE(III) (La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, and Yb) ions over a Ni sheet electrode in 0.1 M NaClO₄ electrolyte solution by cyclic voltammetry between +0.5 and −1.5 V (vs. Ag/AgCl). Amperometry electrodeposition experiments were performed between −1.2 and −0.9 V to recover RE elements over the Ni sheet. The successfully RE-recovered Ni sheets were fully characterized by scanning electron microscopy, energy dispersive X-ray spectroscopy, Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy, and photoluminescence spectroscopy. The newly reported recovery data for RE(III) ions over a metal electrode provide valuable information on the development of the treatment methods of RE elements.     

Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE,DANAMI 2, MADIT-2, MIRACLE-ICD,OVERTURE, OCTAVE,ENABLE 1 & 2, CHRISTMAS,AFFIRM, RACE,WIZARD, AZACS,REMATCH, BNP trial and HARDBALL

This article continues a series of reports updating recent research developments of particular interest to personnel involved in the treatment and management of patients with heart failure. This is a summary of selected presentations made at the American College of Cardiology 51st Annual Scientific Session held in Atlanta on 17-20 March 2002. Reports of the following clinical studies are included: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL.     

Prevalence,Self-Awareness,Treatment, and Control of Hypertension in Lhasa,Tibet

To investigate the prevalence, self-awareness, and treatment of hypertension in Lhasa, Tibet, a total of 1370 native Tibetan aged ≥18 years were selected, using stratified proportional sampling. The study showed that the prevalence of hypertension was 51.2%, significantly higher in men (56.0%) than in women (48.0%) (P = .004). The hypertension prevalence increased with increasing age (77.8% in 60–74 y and 82.5% in ≥75 y groups) and was higher in urban, suburban, or agricultural area than in pastoral area (P < .001). The self-awareness, treatment, and control rate of hypertension were 63.5%, 24.3% and 7.7%, respectively. In multivariable regression analysis, age, urban residence, amount of daily intake of fat and oil, and body mass index <18.5 kg/m² were independently associated with hypertension. In conclusion, hypertension was highly prevalent among native Tibetan people in Lhasa, and the rates of self-awareness, treatment, and control of hypertension were low.     

Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin,atenolol, enalapril,phenytoin, rosiglitazone,and sitagliptin

Aims

Drug interactions with bile acid sequestrants are primarily due to the potential of these agents to bind to concomitant drugs. Six clinical studies were performed to determine the effects of colesevelam on the pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.

Methods

All six studies enrolled healthy subjects aged 18–45 years. The phenytoin study used a single-dose, three-period crossover design (phenytoin alone, phenytoin simultaneously with colesevelam, and phenytoin 4 h before colesevelam). The other studies used a two-period crossover design (test drug alone and test drug simultaneously with colesevelam). Colesevelam (3750 mg once daily) was dosed throughout the pharmacokinetic sampling period. After each single dose of the test drug, serial blood samples were collected for determination of plasma drug concentrations and calculation of pharmacokinetic parameters.

Results

For all six test drugs, 90% CIs for geometric least-squares mean ratios of AUC and C_max for the measured analytes were within specified limits, indicating no interaction between the test drug and colesevelam.

Conclusions

Aspirin, atenolol, enalapril, rosiglitazone, and sitagliptin may be taken with colesevelam. Although the phenytoin study indicated no pharmacokinetic interaction, phenytoin should continue to be taken ≥4 h before colesevelam in accordance with current prescribing information.     

Biliary microlithiasis,sludge,crystals,microcrystallization,and usefulness of assessment of nucleation time

BACKGROUND:The process of microcrystallization,its sequel and the assessment of nucleation time is ignored.This systematic review aimed to highlight the importance of biliary microlithiasis,sludge,and crystals,and their association with gallstones,unexplained biliary pain,idiopathic pancreatitis, and sphincter of Oddi dysfunction.DATA SOURCES:Three reviewers performed a literature search of the PubMed database.Key words used were"biliary microlithiasis","biliary sludge","bile crystals","cholesterol crystallisation","bile microscopy","microcrystal formation of bile","cholesterol monohydrate crystals","nucleation time of cholesterol","gallstone formation","sphincter of Oddi dysfunction"and"idiopathic pancreatitis".Additional articles were sourced from references within the studies from the PubMed search.RESULTS:We found that biliary microcrystals account for almost all patients with gallstone disease,7%to 79%with idiopathic pancreatitis,83%with unexplained biliary pain, and 25%to 60%with altered biliary and pancreatic sphincter function.Overall,the detection of biliary microcrystals in gallstone disease has a sensitivity ranging from 55%to 87%and a specificity of 100%.In idiopathic pancreatitis,the presence of microcrystals ranges from 47%to 90%.A nucleation time less than 10 days in hepatic bile or ultra-filtered gallbladder bile has a specificity of 100%for cholesterol gallstone disease.CONCLUSIONS:Biliary crystals are associated with gallstone disease,idiopathic pancreatitis,sphincter of Oddi dysfunction, unexplained biliary pain,and post-cholecystectomy biliary pain.Pathways of cholesterol super-saturation,crystallisation, and gallstone formation have been described with scientificsupport.Bile microscopy is a useful method to detect microcrystals and the assessment of nucleation time is a good method of predicting the risk of cholesterol crystallisation.     

Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE

This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the American College of Cardiology. Unpublished reports should be considered as preliminary data, as analyses may change in the final publication. CARISMA investigated the use of implantable loop recorders for detecting life-threatening arrhythmias in patients with LVSD after MI and found that brady- and ventricular tachy-arrhythmias predicted an adverse prognosis. The TRENDS study showed that the burden of atrial fibrillation detected by pacemakers or defibrillators predicted the risk of embolic events but not with sufficient precision to justify changes in anti-thrombotic management. A meta-analysis of six trials reported an increased cardiovascular risk associated with celecoxib, particularly for heart failure, which was related to dose and baseline cardiovascular risk. The HAT study failed to show a benefit of providing post-MI patients with a home defibrillator. MOMENTUM, a study of a device designed to augment aortic blood flow, was stopped early due to increased bleeding risk. Results from PROTECT support the use of rolofylline 30 mg/day in acute heart failure, a definitive study is now underway. Istaroxime, an agent that appears to have both inotropic and lusitropic effects, improved haemodynamics when added to standard therapy in patients stabilised after admission with heart failure in HORIZON-HF. The REVERSE study suggested that CRT improves ventricular function and reduces morbidity even in patients with few or no symptoms of heart failure and may delay or prevent worsening heart failure.